Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. (CARM) generates news primarily as a clinical-stage biopharmaceutical company that has focused on engineered macrophage and monocyte immunotherapies and, more recently, on corporate restructuring and wind down activities. News coverage of CARM reflects both its scientific developments and its significant corporate and listing transitions.
On the scientific side, Carisma has issued press releases on preclinical and clinical milestones across oncology and fibrosis. These include data on CT-0525, an ex vivo CAR-monocyte therapy for HER2-overexpressing solid tumors, CT-1119 for mesothelin-positive tumors, and engineered macrophage programs for liver fibrosis. The company has also reported preclinical results from its anti-GPC3 in vivo CAR-M program for hepatocellular carcinoma, developed in collaboration with Moderna, highlighting tumor-targeting activity and off-the-shelf potential.
Carisma news has also covered conference participation, with company representatives presenting at events such as the Society for Immunotherapy of Cancer (SITC), the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, and healthcare investor conferences hosted by firms like Oppenheimer, Evercore ISI, and H.C. Wainwright. These announcements often summarize new data, poster presentations, and updates on the company’s pipeline strategy.
More recent news has focused on strategic alternatives, restructuring, and listing status. Carisma has announced workforce reductions, the pausing or discontinuation of certain programs, and a revised operating plan centered on evaluating strategic options and preserving capital. Additional releases have detailed the company’s noncompliance with Nasdaq listing requirements, the suspension of trading on Nasdaq, the commencement of trading on the OTCID market tier, and the Board’s decision to voluntarily delist and deregister its common stock as part of an orderly wind down of operations.
Investors and observers following the CARM news feed can review this sequence of scientific, strategic, and regulatory announcements to understand how Carisma’s macrophage engineering platform evolved, how its collaboration with Moderna changed over time, and how the company moved from active development to asset monetization and wind down planning.
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors. Sohanya Cheng, MBA will join the board effective October 31, 2024, while Michael Torok will step down on the same date due to other professional commitments. Board Chair Sanford Zweifach highlighted Cheng's experience in oncology, leadership, strategic planning, and commercialization as valuable assets for advancing the company's portfolio. Cheng expressed enthusiasm about supporting Carisma's mission in developing innovative immunotherapies and strengthening its position in engineered macrophages.
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company, has announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2024 in Houston, Texas, from November 6-10. The company will present two posters:
1. Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma (Publication Number: 329)
2. A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors (Publication Number: 659)
Both presentations are scheduled for Friday, November 8, 2024, at the Exhibit Halls A B George R. Brown Convention Center. The posters will be available on Carisma's website in the 'Publications' section following the start of the poster session.
Carisma Therapeutics Inc. (Nasdaq: CARM) has expanded its collaboration with Moderna, Inc. (Nasdaq: MRNA) to develop in vivo CAR-M therapies for autoimmune diseases. This expansion builds on their successful pre-clinical oncology data and includes the nomination of two autoimmune disease targets by Moderna. Carisma will receive research funding and is eligible for milestone and royalty payments.
The collaboration leverages Carisma's proprietary CAR-M technology and Moderna's mRNA/LNP platform. Carisma will handle discovery and optimization of development candidates, while Moderna will lead clinical development and commercialization. This partnership aims to revolutionize treatments for autoimmune conditions, expanding the potential of CAR-M technology beyond oncology.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, has announced its participation in four upcoming healthcare conferences. Steven Kelly, President and CEO, will represent the company at these events:
1. Baird 2024 Global Healthcare Conference on September 10 at 12:50 PM ET in New York, NY
2. H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 1:30 PM ET in New York, NY
3. Chardan's 8th Annual Genetic Medicines Conference on September 30 at 4:00 PM ET in New York, NY
4. The Cell & Gene Meeting on the Mesa on October 7 at 9:30 AM MST in Phoenix, AZ
Live webcasts of these presentations will be available on Carisma's Investor Events webpage, with replays archived for a time after each event.
Carisma Therapeutics (Nasdaq: CARM) reported Q2 2024 financial results and business highlights. Key points include:
- Initial data for CT-0525, their lead anti-HER2 product, expected by year-end 2024
- Nomination of a liver fibrosis development candidate expected in Q1 2025
- First in vivo CAR-M candidate targeting Glypican-3 for hepatocellular carcinoma nominated under Moderna collaboration
- Cash position of $40.4 million, plus $2.0 million from Moderna, expected to fund operations into Q3 2025
- Q2 2024 net loss of $11.2 million, compared to $19.9 million in Q2 2023
- R&D expenses decreased to $15.3 million from $18.5 million year-over-year
- G&A expenses slightly decreased to $5.6 million from $6.0 million year-over-year
Carisma Therapeutics (Nasdaq: CARM) has announced an upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. The event will take place in San Diego, California, from November 15 to 19, 2024.
The presentation, titled 'Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models', is scheduled for November 17, 2024, from 8:00 am to 5:00 pm. It falls under the session 'MASLD/MASH - Therapeutics: New Agents' and has been assigned the publication number 3214.
Carisma Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing innovative immunotherapies. The poster will be available on the company's website in the 'Publications' section following the start of the poster session.
Carisma Therapeutics Inc. (Nasdaq: CARM) has expanded its Scientific Advisory Board (SAB) by appointing two renowned key opinion leaders in liver fibrosis, Dr. Scott Friedman and Dr. Ira Tabas. This strategic move aims to bolster Carisma's program in developing innovative treatments for advanced liver disease. Steven Kelly, President and CEO of Carisma, expressed enthusiasm about leveraging the extensive experience and groundbreaking research of these experts to enhance the company's efforts in creating engineered macrophage therapies. The addition of these prominent figures to the SAB is expected to provide valuable insights and expertise as Carisma continues its mission to develop transformative treatments for patients.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the appointment of Marella Thorell and Dr. David Scadden to its Board of Directors, effective June 30, 2024. This decision coincides with the resignation of Regina Hodits and Björn Odlander due to other professional commitments. Carisma's leadership highlighted the vast experience that Thorell and Scadden bring to the company, which is expected to enhance the advancement of its cell therapy platform focused on engineered macrophages. The company expressed gratitude to the outgoing board members for their contributions.
Carisma Therapeutics (Nasdaq: CARM) has announced the nomination of the first in vivo CAR-M development candidate, targeting Glypican-3 (GPC3), under its collaboration with Moderna. This candidate is designed to treat solid tumors, including hepatocellular carcinoma (HCC), the fastest-rising cause of cancer-related death in the U.S.
This nomination triggers a $2 million milestone payment to Carisma and leverages Carisma's expertise in engineering CAR-M with Moderna's mRNA and lipid nanoparticle platform. Pre-clinical data show the candidate can create CAR-M directly in vivo, redirecting myeloid cells to attack cancer cells.
The program advances under the 2022 strategic collaboration agreement between Carisma and Moderna, aiming to discover and commercialize in vivo CAR-M therapeutics. Moderna has also nominated four additional undisclosed oncology research targets under this collaboration.
Carisma Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced its participation in the Stifel 2024 Cell Therapy Forum.
Steven Kelly, President and CEO, will engage in a fireside chat on July 9, 2024, at 9:10 am ET. This session will be available via an audio webcast on the Investor Events section of Carisma's Investor Relations webpage and will remain archived for a period.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
